- Correlation between homologous recombination repair gene mutation and immunotherapy efficacy in patients with advanced melanoma.You, Changxuan; Zhou, Chengzhi; You, Zhixuan; Lv, Meng; He, Xuanyu; Pan, Yingqin; Ge, Junfeng; Hu, Xue; Zheng, Yating; Huang, MengliAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
- ZFHX4 mutation as a novel predictive biomarker for immune checkpoint blockade in non-small cell lung cancer.Shen, Peng; Zeng, Di; Lin, Zhenzi; Lin, Pei; Luo, Mingyang; Zhao, Lele; Chai, Huizi; Huang, Lingli; Xiao, MingzheAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
- Intratumoral heterogeneity as a predictive biomarker in immunotherapy for advanced non-small cell lung cancer.Xiao, HaiPing; Chen, Kai; Zheng, Yating; Huang, MengliAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
会议论文
PALB2 mutation as a predictive biomarker for immunotherapy in patients with advanced melanoma: Results from (a pooled analysis of) five multicenter, randomized clinical trials.
1被引6阅读
